Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming Sidoti & Co. Micro Cap Virtual Conference By: Investor Brand Network August 11, 2023 at 10:47 AM EDT Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, will be presenting at this month’s Sidoti & Co. Micro Cap Virtual Conference. The two-day event is scheduled for Aug. 16–17, 2023. According to the announcement, PCSA’s president of research and development, David Young, will attend the conference and will present on Processa Pharmaceuticals at 11:30 a.m. ET on Aug. 17. In addition to Young’s presentation, company officials including CEO George NG will be available for one-on-one meetings with potential investors and other interested parties. To view the presentation, visit https://ibn.fm/GaMaa To view the full press release, visit https://ibn.fm/PnUzI About Processa Pharmaceuticals Inc. Processa is a clinical-stage pharmaceutical company focused on developing the next-generation chemotherapy (“NGC”) drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also will increase the probability of FDA approval for its next-generation chemotherapy drugs following an efficient path to approval. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company’s approach to drug development is based on more than 30 years of drug-development expertise to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. Using its proven Regulatory Science Approach, the company has experience defining the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology initiative. The advantages of Processa’s NGC drugs are expected to include fewer patients experiencing side effects that lead to dose discontinuation; more significant cancer response; and a greater number of patients who will benefit from each NGC drug. Currently in the company pipeline are three NGC drugs: Next Generation Capecitabine (PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast and other cancers), and Next Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic and other cancers). For more information, visit the company’s website at www.ProcessaPharma.com. NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA About InvestorWire InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily. For more information, please visit https://www.InvestorWire.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer InvestorWire (IW)8033 Sunset Blvd Suite 1037-IWLos Angeles, CA 90046310.299.1717 Officewww.InvestorWire.comEditor@InvestorWire.com InvestorWire is part of the InvestorBrandNetwork Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming Sidoti & Co. Micro Cap Virtual Conference By: Investor Brand Network August 11, 2023 at 10:47 AM EDT Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, will be presenting at this month’s Sidoti & Co. Micro Cap Virtual Conference. The two-day event is scheduled for Aug. 16–17, 2023. According to the announcement, PCSA’s president of research and development, David Young, will attend the conference and will present on Processa Pharmaceuticals at 11:30 a.m. ET on Aug. 17. In addition to Young’s presentation, company officials including CEO George NG will be available for one-on-one meetings with potential investors and other interested parties. To view the presentation, visit https://ibn.fm/GaMaa To view the full press release, visit https://ibn.fm/PnUzI About Processa Pharmaceuticals Inc. Processa is a clinical-stage pharmaceutical company focused on developing the next-generation chemotherapy (“NGC”) drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also will increase the probability of FDA approval for its next-generation chemotherapy drugs following an efficient path to approval. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company’s approach to drug development is based on more than 30 years of drug-development expertise to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. Using its proven Regulatory Science Approach, the company has experience defining the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology initiative. The advantages of Processa’s NGC drugs are expected to include fewer patients experiencing side effects that lead to dose discontinuation; more significant cancer response; and a greater number of patients who will benefit from each NGC drug. Currently in the company pipeline are three NGC drugs: Next Generation Capecitabine (PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast and other cancers), and Next Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic and other cancers). For more information, visit the company’s website at www.ProcessaPharma.com. NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA About InvestorWire InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily. For more information, please visit https://www.InvestorWire.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer InvestorWire (IW)8033 Sunset Blvd Suite 1037-IWLos Angeles, CA 90046310.299.1717 Officewww.InvestorWire.comEditor@InvestorWire.com InvestorWire is part of the InvestorBrandNetwork
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, will be presenting at this month’s Sidoti & Co. Micro Cap Virtual Conference. The two-day event is scheduled for Aug. 16–17, 2023. According to the announcement, PCSA’s president of research and development, David Young, will attend the conference and will present on Processa Pharmaceuticals at 11:30 a.m. ET on Aug. 17. In addition to Young’s presentation, company officials including CEO George NG will be available for one-on-one meetings with potential investors and other interested parties. To view the presentation, visit https://ibn.fm/GaMaa To view the full press release, visit https://ibn.fm/PnUzI About Processa Pharmaceuticals Inc. Processa is a clinical-stage pharmaceutical company focused on developing the next-generation chemotherapy (“NGC”) drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also will increase the probability of FDA approval for its next-generation chemotherapy drugs following an efficient path to approval. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company’s approach to drug development is based on more than 30 years of drug-development expertise to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. Using its proven Regulatory Science Approach, the company has experience defining the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology initiative. The advantages of Processa’s NGC drugs are expected to include fewer patients experiencing side effects that lead to dose discontinuation; more significant cancer response; and a greater number of patients who will benefit from each NGC drug. Currently in the company pipeline are three NGC drugs: Next Generation Capecitabine (PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast and other cancers), and Next Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic and other cancers). For more information, visit the company’s website at www.ProcessaPharma.com. NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA About InvestorWire InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily. For more information, please visit https://www.InvestorWire.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer InvestorWire (IW)8033 Sunset Blvd Suite 1037-IWLos Angeles, CA 90046310.299.1717 Officewww.InvestorWire.comEditor@InvestorWire.com InvestorWire is part of the InvestorBrandNetwork